Alkem takes majority stake in Swiss medtech firm Occlutech
What's the deal? Alkem LaboratoriesDealroom has a profile for this one. Try Dealroom → has completed its acquisition of a controlling stake in Occlutech Holding AG, a Swiss medtech company, through its wholly owned subsidiary Alkem MedtechDealroom has a profile for this one. Try Dealroom → Private Limited. The deal covers at least 51% and up to 55% of Occlutech's equity, making it a step-down subsidiary of Alkem.
Why now? The closure caps a process Alkem first flagged to Indian stock exchanges on February 13, 2026, with further updates on March 6 and June 29.
What's the endgame? The acquisition extends Alkem's reach into new regions and diversifies its operations. Occlutech now sits inside Alkem's corporate structure, opening potential new product lines.
What could go wrong? Terms including the price were not disclosed, leaving the deal's value unclear. Integrating a Swiss firm into an Indian pharmaceutical group also carries execution risk.
Alkem has published full disclosure on its website under SEBI (Listing Obligations and Disclosure Requirements) Regulations. Manish Narang, president of legal and company secretary, confirmed all records are available.
The signal: The deal marks another Indian pharmaceutical player buying into overseas medtech to broaden its portfolio beyond generics.
Read more: Business Upturn
